Human factor IX transgenic sheep produced by transfer of nuclei from transfected fetal fibroblasts

Science

Volumn 278, Issue 5346, 1997, Pages 2130-2133

  Schníeke, Angelika E ^a   Kind, Alexander J ^a   Ritchie, William A ^b   Mycock, Karen ^a   Scott, Angela R ^a   Ritchie, Marjorie ^b   Wilmut, Ian ^b   Colman, Alan ^a   Campbell, Keith H S ^b  

^a PPL Therapeutics   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 9;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; FETUS; FIBROBLAST; LAMB; MICROINJECTION; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; PRONUCLEUS; TRANSGENE;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; CLONING, ORGANISM; DRUG RESISTANCE; EMBRYO TRANSFER; FACTOR IX; FEMALE; FETUS; FIBROBLASTS; GENTAMICINS; HUMANS; MALE; MILK; NEOMYCIN; NUCLEAR TRANSFER TECHNIQUES; OOCYTES; RECOMBINANT PROTEINS; SHEEP; TRANSFECTION; TRANSGENES;

ANIMALIA; OVIS; OVIS ARIES;

EID: 2642705886     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.278.5346.2130     Document Type: Article

References (35)

1. R. E. Hammer et al., Nature 315, 680 (1985).
2. W. H. Eyestone, Reprod. Fert. Dev. 6, 647 (1994).
3. S. Damak, H. Su, N. P. Jay, D. W. Bullock, Bio/Technology 14, 185 (1996).
4. R. Ramirez-Solis and A. Bradley, Curr. Opin. Biol. 5, 528 (1994).
5. E. P. Brandon, R. L. Idzerda, G. S. McKnight, Curr. Biol. 5, 625 (1995); ibid., p. 758; ibid., p. 873.
6. E. P. Brandon, R. L. Idzerda, G. S. McKnight, Curr. Biol. 5, 625 (1995); ibid., p. 758; ibid., p. 873.
7. E. P. Brandon, R. L. Idzerda, G. S. McKnight, Curr. Biol. 5, 625 (1995); ibid., p. 758; ibid., p. 873.
8. E. Notarianni, C. Galli, S. Laurie, R. M. Moore, M. J. Evans, J. Reprod. Fertil. 43, 255 (1991).
9. M. B. Wheeler, Reprod. Fertil. Dev. 6, 563 (1994).
10. R. W. Gerfen and M. B. Wheeler, Animal Biotechnol. 6, 1 (1995).
11. S. L. Stice, N. S. Strelchenko, C. L. Keefer, L. Mathew, Biol. Reprod. 54, 100 (1996).
12. H. Shim, A. Gutierrez-Adan, L. R. Chen, R. H. Bon-Durant, G. B. Anderson, Theriogenology 47, 245 (1997).
13. J. B. Cibelli et al., ibid., p. 241.
14. K. H. S. Campbell, J. McWhir, W. A. Ritchle, I. Wilmut, Nature 380, 64 (1996).
15. I. Wilmut, A. E. Schnieke, J. McWhir, A. J. Kind, K. H. S. Campbell, ibid. 385, 810 (1997).
16. D. N. Wells, P. M. Misica, A. M. Day, H. R. Tervit, Biol. Reprod. 57, 385 (1997).
17. G. G. Brownlee, Biochem. Soc. Trans. 15, 1 (1987).
18. For construction of pMIX1, human FIX DNA from an Nhe I site at position 2982 to a Bst BI site at position 33,840 (positions refer to EMBL database file HSFIXG) was derived from overlapping genomic λ clones. A 3′ fragment from the Bst BI site to position 34,346 was derived by PCR amplification and a Xho I site introduced. The 31.36-kb fragment containing the FIX coding region was assembled in Bluescript KS-vector (Stratagene) that had been digested with Xba I and Xho I. The entire FIX gene was then excised as a Not I-Xho I fragment and inserted into the ovine BLG expression vector pMADS+ that had been digested with Not I and Xho I. The pMADS+ vector consists of 4.2 kb of BLG promoter sequence, 30 bp of 5′ untranscribed region, a multicloning site (Eco RV, Not I, BgI II, Nhe I, Xho I, Cla I), 170 bp of 3′ untranscribed region including a polyadenylate addition site, and 2 kb of 3′ flanking region cloned into pUC18, containing a modified polylinker to allow excision of the insert with either MIu I or Pvu I.
19. S. Yoshitake, B. G. Schach, D. C. Foster, E. W. Davie, K. Kurachi, Biochemistry 24, 3736 (1985).
20. A. S. Carver et al., Bio/Technology 11, 1263 (1993).
21. Transgenic mice were produced by microinjection of a 37.8-kb MIu I fragment of pMIX1 into the male pronucleus of fertilized mouse oocytes. Milk was collected from transgenic founder females at day 10 postpartum. FIX protein in milk was assayed by enzyme-linked immunosorbent assay with polyclonal rabbit antiserum to human FIX (Dako) and quantified by comparison with purified human FIX standard (Diagnostica Stago).
22. F. Yull et al., Proc. Natl. Acad. Sci. U.S.A. 92, 10899 (1995).
23. S. Jallat et al., EMBO J. 9, 3295 (1990).
24. 5 PDFF2 cells were plated into a 3.5-cm-diameter well and cotransfected with 0.5 μg of PGKneo and 1.5 μg of MIu I-digested pMIX1 DNA with the use of Lipofectamine (Gibco). Forty-eight hours after transfection, cells were split 1:10 and G418 added to a final concentration of 0.6 mg/ml. Transfected PDFF2 cells achieved subconfluence after selection for 6 days. At the third passage, one portion of the cells was split 1:10 and then subjected to selection for an additional 5 days before cryopreservation as an uncloned population. Other portions were split 1:1000 or 1:5000 and subjected to G418 selection for an additional 7 days. Individual colonies were isolated and expanded for cryopreservation at passage 5, and a portion of each clone was grown further for chromosome counting and Southern (DNA) blot analysis.
25. The sex of strains PDFF1 to PDFF7 was determined by PCR, essentially as described [R. Griffiths and B. Tiwari, Mol. Ecol. 2, 405 (1993); B. W. Kirkpatrick and R. L. Monson, J. Reprod. Fert. 98, 335 (1993)].
26. The sex of strains PDFF1 to PDFF7 was determined by PCR, essentially as described [R. Griffiths and B. Tiwari, Mol. Ecol. 2, 405 (1993); B. W. Kirkpatrick and R. L. Monson, J. Reprod. Fert. 98, 335 (1993)].
27. Genomic DNA isolated from cloned pMIX1 transfectants was digested with Bam HI and Eco RI and subjected to Southern blot analysis with a 1.8-kb fragment of the BLG promoter.
28. PCNA analysis of serum-deprived cells was performed essentially as described [I. R. Kill et al., J. Cell Sci. 100, 869 (1991)].
29. Th. A. M. Kruip and J. H. G. den Daas, Theriogenology 47, 43 (1997).
30. S. K. Walker, K. M. Hartwich, R. F. Seamark, ibid. 45, 111 (1996).
31. R. J. Wall and G. E. Seidel, ibid. 38, 337 (1992).
32. R. A. Bowen et al., Biol. Reprod. 50, 664 (1994).
33. T. Takada et al., Nature Biotechnol. 15, 458 (1997).
34. E. M. Thompson, P. Adenot, F. I. Tsuji, J. P. Renard, Proc. Natl. Acad. Sci. U.S.A. 92, 1317 (1995).
35. We thank J. Bracken and M. Malcolm-Smith for technical assistance in large animal work, H. Bowran and D. McGavin for care of the animals, D. Cottom for providing data on microinjectbn studies, the Animal Sciences Team at PPL Therapeutics for help in deriving the PDFF cells, Y. Gibson and the Small Animal Unit at PPL Therapeutics for generating FIX transgenic mice, S. Bruce for FIX protein analysis, G. G. Brownlee for human FIX genomic λ clones, D. Melton for PGKneo, A. R. Scott for technical assistance with molecular biology, and I. Garner for constructive discussions during the course of the project. The experiments were conducted under the Animals (Scientific Procedures) Act 1986 and with the approval of the Roslin Institute Animal Welfare and Experiments Committee.